Analyst Justin Walsh of JonesTrading reiterated a Buy rating on VolitionRX, boosting the price target to $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Justin Walsh has given his Buy rating due to a combination of factors, including growing validation of VolitionRx’s Nu.Q platform and its expanding clinical applications. He highlights recent milestones such as the Nu.Q Vet Cancer test’s integration with Fuji Vet Systems in Japan and encouraging data showing nucleosome detection from capillary blood in critical care settings, which together support broader adoption potential.
Walsh also underscores that the company’s technology remains under-recognized by the market and could evolve into a standard tool across multiple conditions like sepsis, cancer, and trauma, offering meaningful upside. Using a risk-adjusted DCF framework, he arrives at an implied equity value of $24 per share, reflecting both the platform’s long-term opportunity and higher modeled dilution, and believes that additional partnerships and non-dilutive funding could further enhance shareholder value.
According to TipRanks, Walsh is a 5-star analyst with an average return of 19.0% and a 38.00% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Praxis Precision Medicines, and Atai Beckley N.V..